RED-C 3131 Study
Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C)
SEX AT BIRTH: All
CONDITION: Liver disease, Hepatic encephalopathy, Cirrhosis
LOCATION: UH Cleveland Medical Center
The purpose of this research study is to see if an investigational drug, Rifaximin SSD-40IR, given twice daily, will help delay the first episode of overt hepatic encephalopathy requiring hospitalization in patients with liver cirrhosis and how safe it is to use in people.
Who Can Participate
Participants between 18 to 85 years of age with a diagnosis of liver disease at risk for hepatic encephalopathy may be eligible for this study.